let's throw some ideas around; amicus would have had a look over each and every patient, not knowing obviously if they're on placebo or the drug. However they would see the trend. Sure, they could look at the data and think, this is all a bit mumbo jumbo - we can't really infer whether or not patients are on drug.... let's wait for August. But they haven't, they've thrown decent money at it. They must have seen some decent reductions that can't be replicated by placebo.
This proteinuria analysis isn't like a PUL strength test where patients can try harder to get a better result... where placebo can play a role, or where kids get graded on how well they fold their clothes. This is a scientific analysis of scar tissue to halt or reverse kidney damage.
DXB Price at posting:
50.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)